We have located links that may give you full text access.
Two-surgeon Model in Laparoscopic Pancreaticoduodenectomy.
PURPOSE: Laparoscopic pancreaticoduodenectomy (LPD) is one of the most challenging gastrointestinal surgeries. Herein, we propose a new laparoscopic surgical conception called the 2-surgeon model and share our experience in LPD.
MATERIALS AND METHODS: We began performing LPD using the 2-surgeon model in October 2015. To December 2017, we have performed 203 cases of LPDs using 2-surgeon model. Data associated with demographic characteristics, operative outcomes, and postoperative results were prospectively collected and analyzed retrospectively.
RESULTS: Only 1 patient in our series required to conversion to open surgery. The mean operative time was 318 minute. The estimated blood loss was 108 mL. The overall complication was 26.1%. In total, 41 patients (20.2%) suffered from pancreatic fistula, including 33 cases of grade A, 7 cases of grade B, and 1 case of grade C. The 90-day mortality was 0.5%.
CONCLUSIONS: The 2-surgeon model is safe and feasible for LPD.
MATERIALS AND METHODS: We began performing LPD using the 2-surgeon model in October 2015. To December 2017, we have performed 203 cases of LPDs using 2-surgeon model. Data associated with demographic characteristics, operative outcomes, and postoperative results were prospectively collected and analyzed retrospectively.
RESULTS: Only 1 patient in our series required to conversion to open surgery. The mean operative time was 318 minute. The estimated blood loss was 108 mL. The overall complication was 26.1%. In total, 41 patients (20.2%) suffered from pancreatic fistula, including 33 cases of grade A, 7 cases of grade B, and 1 case of grade C. The 90-day mortality was 0.5%.
CONCLUSIONS: The 2-surgeon model is safe and feasible for LPD.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app